Zhejiang Jiuzhou Pharmaceutical Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Lirong Hua

Chief executive officer

CN¥2.7m

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	3.5%
Management average tenure	3.4yrs
Board average tenure	4.5yrs

Recent management updates

Recent updates

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Apr 11

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Feb 28

CEO

Lirong Hua (55 yo)

no data

Tenure

CN¥2,656,600

Compensation

Ms. Lirong Hua serves as the Chairman of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. and served as its General Manager. Ms. Hua has been Chairman of Ningbo Economic and Technological Development Zone Yuebo T...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Lirong Hua	Chairman & GM	no data	CN¥2.66m	3.55% CN¥ 514.3m
Yujie Sha	Financial Manager	2.9yrs	CN¥1.07m	0.010% CN¥ 1.5m
Huilu Lin	Deputy GM	no data	CN¥1.59m	1.94% CN¥ 281.7m
Yi Jiang Mei	Deputy GM & Director	no data	CN¥2.94m	0.11% CN¥ 16.4m
Bin Wang	Director & VP	no data	CN¥5.35m	0.027% CN¥ 3.9m
Yuanqiang Li	Deputy General Manager	no data	CN¥1.80m	0.016% CN¥ 2.3m
Nonggang Yang	Deputy General Manager	3.4yrs	CN¥1.36m	0.010% CN¥ 1.5m
Minxia Huang	Deputy General Manager	3.4yrs	CN¥1.09m	0.010% CN¥ 1.5m
Gong Chen	Vice President	no data	no data	0.0013% CN¥ 192.8k

3.4yrs

Average Tenure

49yo

Average Age

Experienced Management: 603456's management team is considered experienced (3.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lirong Hua	Chairman & GM	no data	CN¥2.66m	3.55% CN¥ 514.3m
Huilu Lin	Deputy GM	no data	CN¥1.59m	1.94% CN¥ 281.7m
Yi Jiang Mei	Deputy GM & Director	no data	CN¥2.94m	0.11% CN¥ 16.4m
Bin Wang	Director & VP	5.6yrs	CN¥5.35m	0.027% CN¥ 3.9m
Wen Ze Li	Director	3.4yrs	CN¥1.17m	no data
Meng Sheng Sun	Chairman of Supervisory Board	no data	no data	no data
Xiao Hui Hua	Director	9.4yrs	no data	no data
De Lan Kong	Independent Director	6.4yrs	CN¥135.00k	no data
Li Jijin	Independent Director	3.4yrs	CN¥135.00k	no data
Biao Yu	Independent Director	3.4yrs	CN¥135.00k	no data

4.5yrs

Average Tenure

53.5yo

Average Age

Experienced Board: 603456's board of directors are considered experienced (4.5 years average tenure).

Zhejiang Jiuzhou Pharmaceutical Management

Management criteria checks 2/4

Key information

Recent management updates

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.32 in 1Q 2023)

Now 21% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd Just Missed Revenue By 17%: Here's What Analysts Think Will Happen Next

Price target decreased by 13% to CN¥32.14

Now 20% undervalued after recent price drop

Zhejiang Jiuzhou Pharmaceutical Co., Ltd, Annual General Meeting, May 16, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q1, 2024 Results on Apr 25, 2024

Now 24% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) Shares Could Be 32% Above Their Intrinsic Value Estimate

Investor sentiment improves as stock rises 17%

Now 23% overvalued

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Fiscal Year 2023 Results on Apr 09, 2024

Third quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.34 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.38 (vs CN¥0.31 in 2Q 2022)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2023 Results on Aug 15, 2023

First quarter 2023 earnings released: EPS: CN¥0.32 (vs CN¥0.25 in 1Q 2022)

Now 21% undervalued after recent price drop

Price target decreased to CN¥50.46

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.34 (vs CN¥0.24 in 3Q 2021)

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) announces an Equity Buyback for CNY 100 million worth of its shares.

Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it expects to receive CNY 2.5 billion in funding

Second quarter 2022 earnings released: EPS: CN¥0.31 (vs CN¥0.22 in 2Q 2021)

Price target decreased to CN¥63.18

Less than half of directors are independent

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improved over the past week

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHSE:603456) signed Investment Agreement to acquire a 25.8% stake in Nan Jing Kang Chuan Ji Pharmatech Co., Ltd. from Yin Laisheng for CNY 40 million.

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Price target increased to CN¥69.15

Third quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.14 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.04 in 1Q 2020)

New 90-day low: CN¥30.48

Investor sentiment deteriorated over the past week

New 90-day high: CN¥38.24

New 90-day high: CN¥35.97

New 90-day low: CN¥29.09

Third quarter earnings released

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report Q3, 2020 Results on Oct 22, 2020

Zhejiang Jiuzhou Pharmaceutical Co., Ltd announced that it expects to receive CNY 1 billion in funding

Price target raised to CN¥22.95

First half earnings released

Earnings released

Zhejiang Jiuzhou Pharmaceutical Co., Ltd to Report First Half, 2020 Results on Aug 26, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age